-
SUNOVION PHARMACEUTICALS INC. v. TEVA PHARMACEUTICALS USA, INC. et al DC CAFC
- 2:09-cv-01302
- D.N.J.
- Judge: Susan D. Wigenton
+1
- Filed: 03/20/2009
- Closed: 06/26/2013
- Latest Docket Entry: 03/15/2017
- PACER
- Docket updated daily
2
Plaintiffs
24
Defendants
1
Accused
Product
4
Patents-in-Suit
1,560
Days in
Litigation
-
SUNOVION PHARMACEUTICALS INC. v. TEVA PHARMACEUTICALS USA, INC. et al DC CAFC
- 2:09-cv-01302
- D.N.J.
- Judge: Susan D. Wigenton
+1
- Filed: 03/20/2009
- Closed: 06/26/2013
- Latest Docket Entry: 03/15/2017
- PACER
- Docket updated daily
Causes of Action
Infringement
Willful Patent Infringement
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
| Claim | Outcome |
|---|---|
| All challenged claims |
Enforceable and Valid
Entry 342 |
-
Infringement
Dr. Reddy's Lab., Inc.
- 1 Detail
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| DRL’s eszopiclone 1 mg, 2 mg, and 3 mg tablets as generic versions of Sunovion’s Lunesta®Generic 1 mg, 2 mg, 3 mg tablets of eszopiclone pursuant to ANDA No. 91-024 | US 6,444,673 B1 |
1, 2, 8
|
No infringement
Entry 507Entry 480 |
Dr. Reddy's Laboratories Ltd.
- 1 Detail
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| DRL’s eszopiclone 1 mg, 2 mg, and 3 mg tablets as generic versions of Sunovion’s Lunesta®Generic 1 mg, 2 mg, 3 mg tablets of eszopiclone pursuant to ANDA No. 91-024 | US 6,444,673 B1 |
1, 2, 8
|
No infringement
Entry 507Entry 480 |
Glenmark Generics Incorporated USA
- 4 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 2mg3 mg eszopiclone tabletsGeneric 1 mg | US 6,319,926 B1 | All Asserted Claims |
Infringement
Entry 307
|
| 2mg3 mg eszopiclone tabletsGeneric 1 mg | US 6,444,673 B1 | All Asserted Claims |
Infringement
Entry 307
|
| 2mg3 mg eszopiclone tabletsGeneric 1 mg | US 6,864,257 B2 | All Asserted Claims |
Infringement
Entry 307
|
| 2mg3 mg eszopiclone tabletsGeneric 1 mg | US 7,381,724 B2 | All Asserted Claims |
Infringement
Entry 307
|
Glenmark Generics Limited
- 4 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 2mg3 mg eszopiclone tabletsGeneric 1 mg | US 6,319,926 B1 | All Asserted Claims |
Infringement
Entry 307
|
| 2mg3 mg eszopiclone tabletsGeneric 1 mg | US 6,444,673 B1 | All Asserted Claims |
Infringement
Entry 307
|
| 2mg3 mg eszopiclone tabletsGeneric 1 mg | US 6,864,257 B2 | All Asserted Claims |
Infringement
Entry 307
|
| 2mg3 mg eszopiclone tabletsGeneric 1 mg | US 7,381,724 B2 | All Asserted Claims |
Infringement
Entry 307
|
Glenmark Pharmaceuticals Limited
- 4 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 2mg3 mg eszopiclone tabletsGeneric 1 mg | US 6,319,926 B1 | All Asserted Claims |
Infringement
Entry 307
|
| 2mg3 mg eszopiclone tabletsGeneric 1 mg | US 6,444,673 B1 | All Asserted Claims |
Infringement
Entry 307
|
| 2mg3 mg eszopiclone tabletsGeneric 1 mg | US 6,864,257 B2 | All Asserted Claims |
Infringement
Entry 307
|
| 2mg3 mg eszopiclone tabletsGeneric 1 mg | US 7,381,724 B2 | All Asserted Claims |
Infringement
Entry 307
|
Roxane Laboratories Incorporated
- 4 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 2mg3mgEszopiclone 1mg | US 6,319,926 B1 | All Asserted Claims |
Infringement
Entry 363
|
| 2mg3mgEszopiclone 1mg | US 6,444,673 B1 | All Asserted Claims |
Infringement
Entry 363
|
| 2mg3mgEszopiclone 1mg | US 6,864,257 B2 | All Asserted Claims |
Infringement
Entry 363
|
| 2mg3mgEszopiclone 1mg | US 7,381,724 B2 | All Asserted Claims |
Infringement
Entry 363
|
Teva Pharmaceutical Industries Limited
- 4 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| Generic tablets containing 1, 2, and 3 milligrams of eszopiclone | US 6,319,926 B1 | All Asserted Claims |
Infringement
Entry 505
|
| Generic tablets containing 1, 2, and 3 milligrams of eszopiclone | US 6,444,673 B1 | All Asserted Claims |
Infringement
Entry 505
|
| Generic tablets containing 1, 2, and 3 milligrams of eszopiclone | US 6,864,257 B2 | All Asserted Claims |
Infringement
Entry 505
|
| Generic tablets containing 1, 2, and 3 milligrams of eszopiclone | US 7,381,724 B2 | All Asserted Claims |
Infringement
Entry 505
|
Teva Pharmaceuticals USA, Inc.
- 4 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 1, 2, 3 milligram tablets of eszopieloneGeneric tablets containing 1, 2, and 3 milligrams of eszopiclone | US 6,319,926 B1 | All Asserted Claims |
Infringement
Entry 338Entry 505 |
| Generic tablets containing 1, 2, and 3 milligrams of eszopiclone | US 6,444,673 B1 | All Asserted Claims |
Infringement
Entry 505
|
| Generic tablets containing 1, 2, and 3 milligrams of eszopiclone | US 6,864,257 B2 | All Asserted Claims |
Infringement
Entry 505
|
| Generic tablets containing 1, 2, and 3 milligrams of eszopiclone | US 7,381,724 B2 | All Asserted Claims |
Infringement
Entry 505
|
Wockhardt Limited
- 4 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 2mg3mgEszopiclone 1mg | US 6,319,926 B1 | All Asserted Claims |
Infringement
Entry 311
|
| 2mg3mgEszopiclone 1mg | US 6,444,673 B1 | All Asserted Claims |
Infringement
Entry 311
|
| 2mg3mgEszopiclone 1mg | US 6,864,257 B2 | All Asserted Claims |
Infringement
Entry 311
|
| 2mg3mgEszopiclone 1mg | US 7,381,724 B2 | All Asserted Claims |
Infringement
Entry 311
|
Wockhardt USA Incorporated
- 4 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 2mg3mgEszopiclone 1mg | US 6,319,926 B1 | All Asserted Claims |
Infringement
Entry 311
|
| 2mg3mgEszopiclone 1mg | US 6,444,673 B1 | All Asserted Claims |
Infringement
Entry 311
|
| 2mg3mgEszopiclone 1mg | US 6,864,257 B2 | All Asserted Claims |
Infringement
Entry 311
|
| 2mg3mgEszopiclone 1mg | US 7,381,724 B2 | All Asserted Claims |
Infringement
Entry 311
|
Wockhardt USA LLC
- 4 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 2mg3mgEszopiclone 1mg | US 6,319,926 B1 | All Asserted Claims |
Infringement
Entry 311
|
| 2mg3mgEszopiclone 1mg | US 6,444,673 B1 | All Asserted Claims |
Infringement
Entry 311
|
| 2mg3mgEszopiclone 1mg | US 6,864,257 B2 | All Asserted Claims |
Infringement
Entry 311
|
| 2mg3mgEszopiclone 1mg | US 7,381,724 B2 | All Asserted Claims |
Infringement
Entry 311
|
